Glenmark Life Sciences Limited is coming up with an IPO. Go ahead and apply for the IPO on July 27,2021. If you don't have an account Click Here

Incorporated in 2011, Glenmark Life Sciences is the leading manufacturer of Active Pharmaceutical Ingredients (APIs). The company develops, manufactures, and supplies high-quality APIs for cardiovascular disease (CVS), central nervous system disease (CNS), pain management, and diabetes, gastrointestinal disorders, anti-infectives, and other therapeutic areas. It further operates in Contract Development and manufacturing operations (CDMO) to offer services to specialty Pharmaceutical companies.

Its products are being sold in India and also exported to multiple countries i.e. Europe, North America, Latin America, Japan, etc. Currently, it has 4 manufacturing facilities at Ankleshwar and Dahej in Gujarat and Mohol and Kurkumbh in Maharashtra State with an aggregate annual installed capacity of 725.8 KL as of December 31, 2020.

Competitive Strengths:

• Leading manufacturer of selected specialized APIs for chronic therapeutic areas like CVS, CNS, diabetes, and pain management.
• Export products in Europe, Latin America, North America, Japan, and the rest of the world.
• Strong relationship with leading global generic companies.
• Proven track record of strong financial performance.
• High-quality product manufacturing with R&D infrastructure.

Company Promoters:

• Glenmark Pharmaceuticals Limited is the promoter of the company.

Objects of the Issue:

• To make payment of outstanding purchase consideration to the promoter for the spin-off of the API business from the promoter into the company.
• To finance capital expenditure requirements.
• To meet general corporate purposes.
  (Read detailed report)

You can Invest via: